649 related articles for article (PubMed ID: 17558424)
1. Prospects for a dengue virus vaccine.
Whitehead SS; Blaney JE; Durbin AP; Murphy BR
Nat Rev Microbiol; 2007 Jul; 5(7):518-28. PubMed ID: 17558424
[TBL] [Abstract][Full Text] [Related]
2. Tropical diseases. Hunt for dengue vaccine heats up as the disease burden grows.
Normile D
Science; 2007 Sep; 317(5844):1494-5. PubMed ID: 17872423
[No Abstract] [Full Text] [Related]
3. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Martinez DR; Metz SW; Baric RS
Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
[TBL] [Abstract][Full Text] [Related]
4. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
5. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
6. Targets and strategies for vaccine development against dengue viruses.
Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
[TBL] [Abstract][Full Text] [Related]
7. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
8. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
9. Dengue vaccine: a valuable asset for the future.
Jindal H; Bhatt B; Malik JS; S K S
Hum Vaccin Immunother; 2014; 10(8):2245-6. PubMed ID: 25424928
[TBL] [Abstract][Full Text] [Related]
10. Dengue vaccine development by the year 2020: challenges and prospects.
Wilder-Smith A
Curr Opin Virol; 2020 Aug; 43():71-78. PubMed ID: 33086187
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
12. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Yang Y; Meng Y; Halloran ME; Longini IM
Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
[TBL] [Abstract][Full Text] [Related]
13. Review of dengue virus and the development of a vaccine.
Murrell S; Wu SC; Butler M
Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
[TBL] [Abstract][Full Text] [Related]
14. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
[TBL] [Abstract][Full Text] [Related]
15. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.
Durbin AP
Curr Opin Virol; 2020 Aug; 43():79-87. PubMed ID: 33164790
[TBL] [Abstract][Full Text] [Related]
16. Dengue virus vaccine development.
Yauch LE; Shresta S
Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
[TBL] [Abstract][Full Text] [Related]
17. Dengue vaccine prospects: a step forward.
Guy B; Almond J; Lang J
Lancet; 2011 Jan; 377(9763):381-2. PubMed ID: 21277439
[No Abstract] [Full Text] [Related]
18. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
19. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
Lee HC; Butler M; Wu SC
Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
[TBL] [Abstract][Full Text] [Related]
20. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
